New Tau-Targeting Drug Halves Cognitive Decline in Alzheimer's Phase 2 Trial

For decades, the fight against Alzheimer's disease has largely focused on clearing amyloid plaques from the brain. But new results from a highly anticipated clinical trial suggest that targeting a different culprit—toxic tangles of the tau protein—could profoundly alter the disease's course. Detailed data from the Phase 2 CELIA study, presented at the Alzheimer's Association International Conference (AAIC) in London, revealed that the experimental drug diranersen successfully reduced tau levels and significantly slowed cognitive decline in patients with early-stage Alzheimer's.[1][5]

The findings represent a major milestone in neurodegenerative research. While recently approved therapies like lecanemab and donanemab have proven that removing amyloid can modestly slow the disease, diranersen is the first therapy to demonstrate that lowering tau provides a robust clinical benefit in a randomized, placebo-controlled trial. Researchers described the data as some of the most compelling evidence to date that tau pathology can be translated into meaningful cognitive preservation.[3][4][5]

Diranersen, developed by Biogen in partnership with Ionis Pharmaceuticals, operates through a distinct mechanism known as an antisense oligonucleotide (ASO). Rather than using antibodies to clear existing protein clumps, the drug acts as a genetic silencer. It binds to the messenger RNA transcribed from the MAPT gene, promoting its degradation and effectively halting the production of the tau protein before it can accumulate into toxic tangles inside brain cells.[2][6][7]

The 18-month CELIA trial enrolled 416 participants aged 50 to 80 who had mild cognitive impairment or mild dementia due to Alzheimer's disease. Participants were randomized to receive either a placebo or one of three doses of diranersen, administered via spinal injection every 12 or 24 weeks. The results showed consistent and reproducible reductions in tau across every dose tested, confirming that the drug successfully reached its target in the central nervous system.[1][2][6][7]

The biomarker data provided clear evidence of target engagement. Participants taking diranersen experienced a 50% to 65% reduction in total tau levels in their cerebrospinal fluid compared to baseline. Furthermore, a substudy utilizing PET imaging revealed decreased tau signals across all evaluated brain regions, making diranersen the first tau-directed therapy to demonstrate reductions in both fluid biomarkers and brain pathology in a Phase 2 setting.[3][6][7]

The most striking results, however, were seen in the clinical assessments of cognitive and functional decline. Across multiple standardized measures, patients receiving diranersen declined more slowly than those on the placebo. The drug's efficacy was most pronounced in the lowest dose group, which received 60 milligrams every 24 weeks.[2][3][6]

In this low-dose cohort, participants experienced a 50% slowing of decline on the Mini-Mental State Examination (MMSE), a widely used test of cognitive function. They also showed a 42% slowing of decline on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13), and a 26% slowing on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), which measures both cognition and daily functioning.[2][3][4]

Despite these strong clinical signals, the trial technically missed its formal primary endpoint. The study was designed to demonstrate a clear dose-response relationship, operating on the assumption that higher doses of the drug would yield greater cognitive benefits. Instead, researchers observed an inverse pattern: the lowest dose performed best clinically, while the higher doses showed less pronounced cognitive preservation despite achieving similar or greater tau reduction.[2][6]

This unexpected dose-response anomaly has introduced a layer of transparent uncertainty into the findings. Some analysts and researchers have questioned whether suppressing tau production too aggressively might interfere with the protein's normal, healthy functions in the brain, potentially offsetting the benefits of clearing the toxic tangles. The exact reason for the inverse response remains an active area of investigation as the drug moves forward.[7]

The safety profile of diranersen was generally consistent with earlier Phase 1 testing, with most adverse events reported as mild or moderate. Common side effects included procedural pain from the lumbar puncture and fatigue. Notably, the trial reported no cases of ARIA (amyloid-related imaging abnormalities)—the brain swelling and bleeding frequently associated with anti-amyloid antibody treatments. However, researchers did note instances of a confusional state, which occurred more frequently in the highest-dose groups and typically resolved within a week.[2][3][6]

The success of diranersen stands in stark contrast to a string of recent failures in the tau-targeting space. Several high-profile monoclonal antibodies designed to clear extracellular tau, such as posdinemab and bepranemab, have recently failed to show cognitive benefits in Phase 2 trials. Experts suggest that diranersen's intracellular approach—stopping tau production at the genetic level rather than trying to clear it after it has been released—may be the key to its clinical efficacy.[6][7]

The implications of these results extend far beyond a single drug. For years, the Alzheimer's field has envisioned a future of combination therapies, similar to how HIV or cancer are treated by targeting multiple pathways simultaneously. With anti-amyloid drugs already on the market, the emergence of a highly effective tau-lowering therapy brings the prospect of a dual-action treatment regimen closer to reality.[1][4][7]

Based on the robust biomarker reductions and the clear signals of clinical benefit, Biogen has announced its intention to advance diranersen into confirmatory Phase 3 clinical trials. More than 90% of the participants who completed the placebo-controlled portion of the CELIA study have opted to continue receiving the drug in a long-term open-label extension, which will provide further data on its safety and durability.[1][3]

While diranersen is not yet available to patients outside of clinical trials, the Phase 2 results offer a powerful validation of the underlying science. After decades of research establishing tau's central role in mediating the harmful effects of Alzheimer's disease, the field now has concrete evidence that intervening in this pathway can meaningfully protect the minds of those facing the condition.[4][5]